OrbiMed Advisors LLC

OrbiMed Advisors LLC is a prominent healthcare investment firm based in New York City, specializing in public and private investments across the healthcare and biotechnology sectors. Founded in 1989, the firm has grown to become one of the world's largest dedicated healthcare investment firms, managing approximately $20 billion in assets as of 2024. OrbiMed's investment approach spans various stages of company development, from seed-stage startups to large multinational corporations, focusing on biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. The firm's global team of over 150 professionals operates across multiple locations, including New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, and Herzliya, enabling OrbiMed to provide tailored financing solutions and extensive resources to its portfolio companies. OrbiMed's investment strategy is comprehensive, targeting companies at various stages of development, from seed-stage startups to large multinational corporations. The firm employs a flexible approach, investing in private equity, public equity, and private credit/royalty funds, aiming to provide tailored financing solutions and extensive global resources to build world-class healthcare companies. OrbiMed has a notable track record, having backed over 110 life sciences startups and committed over $2 billion to developing-country healthcare initiatives. Their portfolio includes companies like ADARx Pharmaceuticals, Treeline Biosciences, Caris Life Sciences, and Biokin. The firm has also been active in raising substantial funds, such as the $1.86 billion raised for Healthcare Royalty & Credit Fund V in 2025, demonstrating strong investor confidence and a commitment to driving innovation in the healthcare sector.

Innovative and growth-oriented opportunities across healthcare sub-sectors, Companies with strong management teams, Potential for significant impact in the healthcare industry, Alignment with OrbiMed's investment strategy and values, Focus on healthcare and biotechnology sectors, Investments across various stages from seed to buyout, Global investment approach with a presence in multiple countries, Commitment to responsible investing and ESG factors, Companies in the healthcare and biotechnology sectors, Global presence, Various stages of development from seed-stage to large multinational corporations